HALO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Halozyme Therapeutics Inc (HALO) is not a strong buy at this moment for a beginner, long-term investor with $50,000-$100,000 available for investment. While the company has positive catalysts such as promising drug delivery technology and strong partnerships, the lack of clear bullish technical signals, hedge fund selling, and neutral insider sentiment suggest holding off on immediate investment.
The MACD is negatively expanding, indicating bearish momentum. RSI is neutral at 39.49, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the stock is trading near a key support level (S1: 67.841), and the price trend shows a 70% chance of a slight decline (-0.85%) in the next day.
Halozyme expects minimal impact from Medicare Drug Price Negotiation Program, ensuring income stability.
Promising drug delivery technologies like Hypercon™ and Surf Bio's technologies.
Strong clinical results from Darzalex Faspro in combination with Johnson & Johnson's Talvey therapy, showing improved survival rates in multiple myeloma patients.
Hedge funds are aggressively selling, with a 4215.85% increase in selling activity last quarter.
Neutral insider sentiment with no significant trading trends.
No recent congress trading data to indicate political confidence in the stock.
Financial data for the latest quarter is unavailable, making it difficult to assess growth trends. However, analysts note solid Q1 results and reiterated guidance for 2026-2028.
Analysts maintain a bullish outlook with price targets ranging from $93 to $96 and Buy/Overweight ratings. Recent updates highlight strong royalty revenue growth and a new share repurchase program.
